First-line targeted therapies in the treatment of metastatic colorectal cancer - role of cetuximab

about

A phase I open-label study of the safety, tolerability, and pharmacokinetics of pazopanib in combination with irinotecan and cetuximab for relapsed or refractory metastatic colorectal cancer.

P2860

Q54320201-BE6DDDB8-E72E-4504-8B47-5B04110DBAA0

P2860

First-line targeted therapies in the treatment of metastatic colorectal cancer - role of cetuximab

Item

http://www.wikidata.org/entity/Q37771245

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 18 February 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

First-line targeted therapies ...... tal cancer - role of cetuximab

@en

First-line targeted therapies ...... al cancer - role of cetuximab.

@nl

type

Item

label

First-line targeted therapies ...... tal cancer - role of cetuximab

@en

First-line targeted therapies ...... al cancer - role of cetuximab.

@nl

prefLabel

First-line targeted therapies ...... tal cancer - role of cetuximab

@en

First-line targeted therapies ...... al cancer - role of cetuximab.

@nl

P1476

First-line targeted therapies ...... tal cancer - role of cetuximab

@en

P2093

Alice Calvieri

http://www.w3.org/2001/XMLSchema#string

Bruno Vincenzi

http://www.w3.org/2001/XMLSchema#string

Giuseppe Tonini

http://www.w3.org/2001/XMLSchema#string

P2860

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

Cetuximab for the treatment of colorectal cancer.

Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study

Epidermal growth factor-related peptides and their receptors in human malignancies

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

EGF-ERBB signalling: towards the systems level

Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer.

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.

P304

73-82

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/OTT.S3465

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P50

Daniele Santini

P577

2009-02-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20616896

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

cetuximab

P932

2886322

http://www.w3.org/2001/XMLSchema#string

First-line targeted therapies in the treatment of metastatic colorectal cancer - role of cetuximab

about

P2860

P2860

First-line targeted therapies in the treatment of metastatic colorectal cancer - role of cetuximab

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P478

P50

P577

P698

P921

P932